Galectin-3, haptoglobin and proangiogenic factors in gastric cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Stomach cancer in Russia occupies the 4th place among most frequent malignant neoplasms, after tumors of the lung, breast and colon. The search for new diagnostic and prognostic markers of this pathology is an urgent task of modern molecular oncology. The purpose of the study is a comprehensive analysis of the content of soluble forms of galectin-3, haptoglobin, as well as pro-angiogenic molecules VEGF, sVEGFR1 and sVEGFR2 in patients with gastric cancer. Material and methods. The study included plasma and serum samples from 60 patients with gastric cancer and from 32 healthy donors. The concentrations of galectin-3, haptoglobin, as well as VEGF, sVEGFR1 and sVEGFR2 were determined using ELISA. The Mann-Whitney test was used to analyze the statistically significant differences in independent groups. Correlation analysis was performed using the Spearman rank correlation coefficient. Overall survival was analyzed by constructing survival curves using the Kaplan-Meier method. Differences were considered statistically significant atp<0.05. Results. The data of a complex comparative study of the content of soluble forms of galectin-3, haptoglobin, as well as VEGF, sVEGFR1 and sVEGFR2 are presented. The diagnostic significance of galectin-3 and haptoglobin was determined. The study showed that the content of galectin-3 and haptoglobin was statistically significantly lower in the group of healthy donors compared to patients with gastric cancer. Further we showed that the content of galectin-3 and haptoglobin is associated with the localization of the tumor in the stomach. Statistically significant correlations were found between the soluble forms of some of the studied markers, indicating the presence of independent mechanisms of their regulation in gastric cancer, which may explain the ambiguous clinical significance for this type of tumor. Conclusion. The results will help to better understand the biology of gastric cancer and improve the efficiency of its diagnostics and therapy.

Full Text

Restricted Access

About the authors

Olga Vladimirovna Kovaleva

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovkovaleva@gmail.com

Senior Researcher, Laboratory of regulation of cellular and viral oncogenes

Russian Federation,

Natalya Nikolaevna Zybina

A.M. Nikiforov All-Russian Center for Emergency and Radiation Medicine of the Ministry of Emergency Situations of Russia

Email: zybinan@inbox.ru

Head of the Department of Laboratory Diagnostics

Russian Federation,

Alexey Nikolaevich Gratchev

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: alexei.gratchev@gmail.com

Head of the Laboratory for tumor stromal cells biology

Russian Federation,

Victor Luisovich Chang

Derzhavin Tambov State University

Email: ken_baxter@mail.ru

Senior Lecturer, Department of Anatomy and Operative Surgery

Russian Federation,

Nikolay Alexeevich Ognerubov

Derzhavin Tambov State University

Email: ognerubov_n.a@mail.ru

Head of the Department of Oncology Medical Institute

Russian Federation,

Ivan Sokratovich Stilidi

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ronc@list.ru

Head

Russian Federation,

Nikolay Evgenievich Kushlinskii

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Author for correspondence.
Email: biochimia@yandex.ru

Head of the Laboratory of Clinical Biochemistry

Russian Federation,

References

  1. De Oliveira F.L., Gatto M., Bassi N., Luisetto R., Ghirardello A., Punzi L. et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 2015; 240 (8): 1019-28. https://doi.org/10.1177/1535370215593826
  2. Newlaczyl A.U., Yu L.G. Galectin-3--a jack-of-all-trades in cancer. Cancer letters. 2011; 313 (2): 123-8. https://doi.org/10.1016/j.canlet.2011.09.003
  3. Colnot C., Fowlis D., Ripoche M.A., Bouchaert I., Poirier F. Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn. 1998; 211 (4): 306-13. https://doi.org/10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L
  4. Dumic J., Dabelic S., Flogel M. Galectin-3: an open-ended story. Biochimica et bio-physica acta. 2006; 1760 (4): 616-35. htt-ps://doi.org/10.1016/j.bbagen.2005.12.020
  5. Sano H., Hsu D.K., Yu L., Apgar J.R., Kuwabara I., Yamanaka T. et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. Journal of immunology. 2000; 165 (4): 2156-64. https://doi.org/10.4049/jimmunol.165.4.2156
  6. John C.M., Jarvis G.A., Swanson K.V., Leffler H., Cooper M.D., Huflejt M.E. et al. Galectin-3 binds lactosaminylated lipooligosac-charides from Neisseria gonorrhoeae and is selectively expressed by mucosal epithelial cells that are infected. Cellular microbiology. 2002; 4 (10): 649-62. https://doi.org/10.1046/j.1462-5822.2002.00219.x
  7. MacKinnon A.C., Farnworth S.L., Hodkinson P.S., Henderson N.C., Atkinson K.M., Leffler H. et al. Regulation of alternative macrophage activation by galectin-3. Journal of immunology. 2008; 180 (4): 2650-8. htt-ps://doi.org/10.4049/jimmunol.180.4.2650
  8. Karlsson A., Christenson K., Matlak M., Bjorstad A., Brown K.L., Telemo E. et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology. 2009; 19 (1): 16-20. https://doi.org/10.1093/gly-cob/cwn104
  9. Pugliese G., Iacobini C., Pesce C.M., Menini S. Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology. 2015; 25 (2): 136-50. https://doi.org/10.1093/glycob/cwu111
  10. Dong R., Zhang M., Hu Q., Zheng S., Soh A., Zheng Y. et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).Int. J. Mol. Med. 2018; 41 (2): 599-614. https://doi.org/10.3892/ijmm.2017.3311
  11. Tao L., Jin L., Dechun L., Hongqiang Y., Changhua K., Guijun L. Galectin-3 Expression in Colorectal Cancer and its Correlation with Clinical Pathological Characteristics and Prognosis. Open Med (Wars). 2017; 12: 226-30. https://doi.org/10.1515/med-2017-0032
  12. Bresalier R.S., Byrd J.C., Tessler D., Lebel J., Koomen J., Hawke D. et al. A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology. 2004; 127 (3): 741-8. https://doi.org/10.1053/j.gastro.2004.06.016
  13. Cheng D., Liang B., Li Y. Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit. 2015; 21: 755-60. https://doi.org/10.12659/MSM.892386
  14. Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D. Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients. J. Gastrointest Cancer. 2016; 47 (2): 182-6. https://doi.org/10.1007/s12029-016-9817-5
  15. Subhash V.V., Ho B. Galectin 3 acts as an enhancer of survival responses in H. pylori-infected gastric cancer cells. Cell Biol Toxicol. 2016; 32 (1): 23-35. https://doi.org/10.1007/s10565-016-9315-3
  16. Sato S., Ohike N., Enosawa T., Sato M., Imataka H., Wada Y. et al. Clinicopatho-logic Significance of Galectin-3 Expression Patterns in Gastric Cancer Patients. The Showa University Journal of Medical Sciences. 2009; 21 (1): 45-53. https://doi.org/10.15369/sujms.21.45
  17. Markowska A.I., Liu F.T., Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. The Journal of experimental medicine. 2010; 207 (9): 1981-93. https://doi.org/10.1084/jem.20090121
  18. D'Haene N., Sauvage S., Maris C., Adanja I., Le Mercier M., Decaestecker C. et al. VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin 3-induced angiogenesis. PloS one. 2013; 8 (6): e67029. https://doi.org/10.1371/journal.pone.0067029

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. А. Comparative analysis of galectin-3 and haptoglobin levels in plasma of patients with gastric cancer and healthy donors. B. ROC analysis for galectin-3 and haptoglobin in patients with gastric cancer: the area under the ROC curve is 0.631 (p=0.0396) for galectin-3 and 0.697 (p=0.0099) for haptoglobin

Download (100KB)
Indexing metadata
3. Fig. 2. Analysis of overall survival depending on plasma galectin-3 and haptoglobin level of gastric cancer patients

Download (84KB)
Indexing metadata
4. Fig. 3. Correlation analysis of the level of galectin-3, haptoglobin, VEGF1, sVEGFR1, sVEGFR2 in gastric cancer patients (Spearman’s rank correlation coefficient)

Download (59KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies